Vaccinated people still get COVID because the vaccines are injected into your arm, not your nose, and the virus enters through your nose. That mismatch is the core reason. The shots train your immune system to fight the virus in your bloodstream and organs, which is why they’re good at preventing severe illness, but they don’t build strong defenses at the exact spot where the virus first lands. On top of that, the virus keeps changing and vaccine-generated antibodies fade over time.
Your Nose and Lungs Have a Different Immune System
When you get a COVID vaccine in your arm, your body produces a type of antibody called IgG that circulates through your blood. These antibodies are excellent at intercepting the virus once it reaches your lungs, heart, or other organs. But the virus doesn’t start there. It starts in the lining of your nose and throat, which has its own separate immune defense that relies on a different antibody called IgA.
Injected vaccines produce very little IgA in the nose. Only direct stimulation of the respiratory lining, through either a nasal vaccine or an actual infection, triggers meaningful IgA production in the upper airways. Without those local antibodies standing guard, the virus can slip in, start replicating in your nasal passages, and cause a symptomatic infection before your bloodstream antibodies even get involved. This is why someone can be fully vaccinated and still develop a sore throat, congestion, and a positive test.
IgA may actually be better than IgG at neutralizing newer variants. At mucosal surfaces, IgA exists in larger, more complex molecular forms that appear to compensate for the virus’s ability to dodge standard antibodies. This makes the gap between what an arm injection provides and what the nose actually needs even more significant.
Antibodies Fade Faster Than You’d Expect
Even the bloodstream antibodies that vaccines do produce don’t stick around indefinitely. After a two-dose mRNA series, antibody levels have a half-life of roughly 60 days, meaning they drop by half about every two months. A booster extends that to around 100 days. People with hybrid immunity (vaccination plus at least one prior infection) fare better, with a half-life of about 241 days, but even their antibodies eventually decline below protective thresholds.
In practical terms, someone with hybrid immunity maintains antibody levels above the 75% protection mark for roughly 283 days, just over nine months, after their last immune-boosting event, whether that was a shot or an infection. After that window closes, the risk of a breakthrough infection climbs. This pattern of waning protection is a major reason breakthrough infections cluster in the months furthest from someone’s last vaccination or infection. CDC data from the 2024-2025 season reflects this: vaccine effectiveness against emergency department visits was 36% in the first two months after a dose and dropped to 30% by months three and four.
The Virus Keeps Changing Shape
COVID vaccines teach your immune system to recognize the spike protein on the surface of the virus. But SARS-CoV-2 mutates constantly, and many of those mutations land right on the spike protein, altering its shape just enough that existing antibodies have a harder time latching on. Each new variant is a slightly different target than the one the vaccine was designed around.
During the 2024-2025 season, the dominant circulating strains (KP.2, KP.3, and XEC) were all descendants of the Omicron JN.1 lineage. The updated vaccines targeted JN.1, but by the time they rolled out, the virus had already moved on to sub-variants with additional spike changes. This cat-and-mouse dynamic between vaccine updates and viral evolution means there’s almost always some degree of mismatch, which reduces the vaccine’s ability to block infection outright.
What Vaccines Still Do Well
The picture looks much better when you shift from “preventing any infection” to “preventing a terrible outcome.” That’s because a second layer of immune defense, your T cells, doesn’t fade as quickly and isn’t as easily fooled by mutations. T cells recognize broader features of the virus than antibodies do, so even when a new variant slips past your antibodies, T cells can still identify infected cells and destroy them.
Memory T cells generated by vaccination spring into action quickly during reinfection, controlling viral replication early before the virus can spread deep into the lungs and trigger dangerous inflammation. This early intervention is why vaccinated people who do catch COVID tend to clear the virus faster. Data from viral load studies shows that while vaccinated and unvaccinated people reach similar peak viral levels during infection, vaccinated individuals clear the virus in an average of 5.5 days compared to 7.5 days for unvaccinated people. That shorter infection window translates to less tissue damage and milder symptoms overall.
A strong memory T cell response also appears to reduce the risk of long COVID. People with a robust pool of these cells are less likely to experience prolonged symptoms, likely because the T cells prevent the kind of chronic inflammation and viral persistence that drive lingering illness.
Some People Are More Vulnerable Than Others
Not everyone mounts the same immune response to vaccination. In a study of over 1.2 million vaccinated adults, those with chronic lung disease had double the risk of breakthrough infection compared to people without underlying conditions. Immunocompromised individuals and those with chronic kidney disease or diabetes faced roughly 1.7 to 1.8 times the risk. These conditions can blunt the immune system’s ability to build and maintain the antibodies and T cells that vaccines are designed to generate.
Age plays a major role as well. Among vaccinated adults who experienced breakthrough infections, 31% were between 65 and 75, and another 31% were between 75 and 85. Only a tiny fraction of breakthrough cases occurred in adults under 35. The aging immune system responds less vigorously to vaccination, produces fewer antibodies, and loses those antibodies more quickly, all of which widen the window for breakthrough infection.
Why Breakthrough Infections Are Usually Milder
If you’re vaccinated and test positive, the infection is playing out differently inside your body than it would without vaccination. Your antibodies may not have blocked the virus at the door, but they’re still present in your bloodstream at some level, slowing the virus down. Meanwhile, your memory T cells are already ramping up, identifying and killing infected cells before the virus can overwhelm your lower respiratory tract.
The result is an infection that peaks at similar viral levels but resolves about two days sooner. Those two days matter: less time at high viral load means less opportunity for the kind of runaway inflammation that sends unvaccinated people to the hospital. Current vaccine effectiveness against emergency visits sits around 33% for preventing the visit entirely, but the protection against the worst outcomes, ICU admission and death, remains substantially higher because T cell immunity is more durable and variant-resistant than antibody-based protection alone.
In short, COVID vaccines were never a force field. They’re more like body armor: the virus can still hit you, but it’s far less likely to take you down.